Hype in Genes
By Matthew Herper,
Forbes
| 07. 11. 2007
Gene celeb Craig Venter is making new breakthroughs at a new institute. Let's hope it doesn't end up like his last one.
J Craig Venter secured his place in the scientific firmament seven years ago when he nearly outran the U.S. government in the race to map the human genome. He's aiming impossibly high again, making big headlines for transplanting the entire genome of one species of bacterium into another. It was hailed by several scientists as a step toward producing the first man-made organism that, according to Venter, could as soon as five years from now help solve global warming by reducing our reliance on fossil fuels.
Venter's transplanting trick was another wow moment at his 500-person gene machine, which goes by an easy-to-remember name, the J. Craig Venter Institute. Its $200 million in assets is funded in part by gains from his biotech business ventures. Venter, 60, is one of the two most mentioned researchers in a recent textbook on recombinant DNA.
Being the Bono of genetics allows him to fund audacious ideas that might otherwise be starved...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...